Compare Glenmark Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FRESENIUS KABI ONCO. GLENMARK PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 12.5 22.1 56.5% View Chart
P/BV x 1.8 3.1 57.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 GLENMARK PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs712176 404.3%   
Low Rs48479 616.1%   
Sales per share (Unadj.) Rs349.637.7 927.7%  
Earnings per share (Unadj.) Rs32.85.1 643.6%  
Cash flow per share (Unadj.) Rs44.36.7 659.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.642.5 466.9%  
Shares outstanding (eoy) m282.17158.23 178.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.73.4 50.6%   
Avg P/E ratio x18.225.0 73.0%  
P/CF ratio (eoy) x13.518.9 71.2%  
Price / Book Value ratio x3.03.0 100.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62520,135 837.5%   
No. of employees `00012.01.2 1,044.9%   
Total wages/salary Rs m20,561703 2,923.9%   
Avg. sales/employee Rs Th8,196.05,176.2 158.3%   
Avg. wages/employee Rs Th1,708.1610.4 279.8%   
Avg. net profit/employee Rs Th768.5699.6 109.8%   
INCOME DATA
Net Sales Rs m98,6555,963 1,654.4%  
Other income Rs m2,08118 11,563.2%   
Total revenues Rs m100,7365,981 1,684.3%   
Gross profit Rs m15,8581,430 1,108.9%  
Depreciation Rs m3,259258 1,263.7%   
Interest Rs m3,346-26 -12,868.8%   
Profit before tax Rs m11,3351,216 932.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-68 -2,454.9%   
Tax Rs m3,756342 1,097.7%   
Profit after tax Rs m9,250806 1,147.8%  
Gross profit margin %16.124.0 67.0%  
Effective tax rate %33.128.1 117.8%   
Net profit margin %9.413.5 69.4%  
BALANCE SHEET DATA
Current assets Rs m66,9685,102 1,312.7%   
Current liabilities Rs m40,2112,385 1,685.7%   
Net working cap to sales %27.145.6 59.5%  
Current ratio x1.72.1 77.9%  
Inventory Days Days83150 55.5%  
Debtors Days Days81113 71.7%  
Net fixed assets Rs m33,3225,148 647.3%   
Share capital Rs m282158 178.4%   
"Free" reserves Rs m55,7706,556 850.7%   
Net worth Rs m56,0526,732 832.6%   
Long term debt Rs m35,738952 3,753.2%   
Total assets Rs m132,88810,388 1,279.2%  
Interest coverage x4.4-45.8 -9.6%   
Debt to equity ratio x0.60.1 450.8%  
Sales to assets ratio x0.70.6 129.3%   
Return on assets %9.57.5 126.3%  
Return on equity %16.512.0 137.8%  
Return on capital %17.814.6 122.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m62,9985,298 1,189.2%   
Fx outflow Rs m22,8591,772 1,289.8%   
Net fx Rs m40,1403,525 1,138.6%   
CASH FLOW
From Operations Rs m13,2421,274 1,039.3%  
From Investments Rs m-6,990-1,204 580.5%  
From Financial Activity Rs m-7,387-196 3,767.2%  
Net Cashflow Rs m-2,971-126 2,352.2%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 6.9 0.3 2,300.0%  
FIIs % 34.4 9.6 358.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   56,727 42,599 133.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Up; Telecom Stocks Rally(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.6% while the Hang Seng is up 0.9%.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 19, 2019 10:35 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS